People: Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

62.68USD
24 May 2013
Price Change (% chg)

$-0.32 (-0.51%)
Prev Close
$63.00
Open
$62.63
Day's High
$63.12
Day's Low
$62.53
Volume
18,958
Avg. Vol
228,834
52-wk High
$64.43
52-wk Low
$40.40

Search Stocks

Summary

Name Age Since Current Position

Bruce Cozadd

 49 2009 Chairman of the Board, Chief Executive Officer

Kathryn Falberg

 52 2012 Chief Financial Officer, Executive Vice President

Suzanne Hooper

 47 2012 Executive Vice President, General Counsel

Russell Cox

 49 2012 Chief Commercial Officer, Executive Vice President

Fintan Keegan

 2012 Senior Vice President - Technical Operations

Jeffrey Tobias

 58 2012 Chief Medical Officer, Executive Vice President - Research and Development

Karen Wilson

 49 2011 Vice President - Finance, Principal Accounting Officer

Heather McSharry

 51 2013 Director

Norbert Riedel

 2013 Director

Peter Gray

 2013 Non-Executive Director

Paul Berns

 46 2010 Independent Director

Patrick Enright

 51 2009 Independent Director

James Momtazee

 41 2004 Independent Director

Seamus Mulligan

 43 2012 Independent Director

Kenneth O'Keefe

 46 2004 Independent Director

Catherine Sohn

 60 2012 Director

Rick Winningham

 53 2010 Independent Director

Katherine Littrell

 Vice President - Investor Relations
» Insider Trading

Biographies

Name Description

Bruce Cozadd

 Mr. Bruce C. Cozadd is Chairman of the Board, Chief Executive Officer of Jazz Pharmaceuticals PLC. He was a co-founder and has served (and continues to serve) as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.’s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. He serves on the boards of Cerus Corporation, a biomedical products company, Threshold Pharmaceuticals, a clinical stage biopharmaceutical company, and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.

Kathryn Falberg

 Ms. Kathryn E. Falberg is Chief Financial Officer, Executive Vice President of Jazz Pharmaceuticals PLC. Prior to the Azur Merger, she served as Jazz Pharmaceuticals, Inc.’s Senior Vice President and Chief Financial Officer since joining Jazz Pharmaceuticals, Inc. in December 2009. From 2003 to 2008, Ms. Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies, and from February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Ms. Falberg currently serves on the boards, and is chair of the audit committees, of the biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc.

Suzanne Hooper

 Ms. Suzanne Sawochka Hooper is Executive Vice President, General Counsel of Jazz Pharmaceuticals PLC. From 1999 through early 2012, she was a partner in the law firm Cooley LLP. Ms. Hooper served for several years as a member of Cooley’s Management Committee and as Vice Chair of the firm’s Business Department. While at Cooley, Ms. Hooper practiced corporate and securities law, primarily with companies and investors in the life sciences industry. Ms. Hooper received a J.D. from the University of California, Berkeley, Boalt Hall School of Law and a B.A. in Political Science from the University of California, Santa Barbara. Ms. Hooper is a member of the State Bar of California.

Russell Cox

 Mr. Russell J. Cox is Chief Commercial Officer, Executive Vice President of Jazz Pharmaceuticals PLC. Prior to the Azur Merger, he served in a variety of senior management roles since joining Jazz Pharmaceuticals, Inc. in 2010. From January 2009 to January 2010, he was Senior Vice President and Chief Commercial Officer of Ipsen Group, and from 2007 until December 2008, he was Vice President of Marketing at Tercica, Inc. (acquired by Ipsen Group), a biotechnology company. From 2003 to 2007, he was with Scios Inc. (acquired by Johnson and Johnson later in 2003), where he also held the role of Vice President, Marketing. Prior to 2003, Mr. Cox was with Genentech, Inc. for 12 years, where he was a Product Team Leader (PTL) responsible for the Growth Hormone franchise and led numerous product launches as a Group Product Manager. Mr. Cox received a B.S. in Biomedical Science from Texas A&M University.

Fintan Keegan

 Mr. Fintan Keegan is Executive Vice President - Technical Operations of Jazz Pharmaceuticals PLC. Prior to the Azur Merger, he was Senior Vice President and Chief Technical Officer of Azur Pharma from 2006 until the Azur Merger, where he was responsible for quality, regulatory, compliance, supply chain and development. Prior to his work with Azur Pharma, Mr. Keegan most recently served as Vice President of Quality and Regulatory for Elan Corporation, plc. He also held various positions with Wyeth Pharmaceuticals, Inc., Merck & Co., Inc. and at a clinical contract research organization. Mr. Keegan holds a B.Sc and a H. Dip in Pharmaceutical Manufacturing Technology from Trinity College Dublin and a M.Sc from the School of Chemistry, University of Bristol, in the United Kingdom.

Jeffrey Tobias

 Dr. Jeffrey K. Tobias, M.D., is Chief Medical Officer, Executive Vice President - Research and Development of Jazz Pharmaceuticals PLC. He has served as Senior Vice President, Research and Development and Chief Medical Officer from the Azur Merger until March 2012. Prior to the Azur Merger, he served as Jazz Pharmaceuticals, Inc.’s Senior Vice President, Research and Development and Chief Medical Officer since joining Jazz Pharmaceuticals, Inc. in October 2011. From January 2010 to October 2011, Dr. Tobias served as Executive Vice President, Research and Development at NeurogesX, Inc.; previously, he served as NeurogesX’s Chief Medical Officer since November 2005. Dr. Tobias was founder and managing director of the Aquila Consulting Group, LLC, a biopharmaceutical consulting firm, from September 1996 to November 2005. Prior to these activities, Dr. Tobias was a Director, New Product Discovery at ALZA Corporation, Director, Clinical Development at Chiron Corporation and Director, Clinical Research at Xoma Corporation. Dr. Tobias received board certification in both Internal Medicine and Pulmonary Medicine and completed training in Critical Care Medicine at the University of California, Los Angeles. He received an M.D. with honors and a B.A. from the University of Illinois.

Karen Wilson

 Ms. Karen J. Wilson is Senior Vice President - Finance, Principal Accounting Officer of Jazz Pharmaceuticals PLC. She has served as Vice President, Finance and Principal Accounting Officer from the Azur Merger until February 2013. Prior to the Azur Merger, she served as Jazz Pharmaceuticals, Inc.’s Vice President, Finance since February 2011 and was appointed Principal Accounting Officer in March 2011. From 2009 to January 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. From 2005 to 2009, she served as a principal at the consulting firm Wilson Crisler LLC. Previously, from 2001 to 2004, she was Chief Financial Officer of ViroLogic, Inc. Prior to joining ViroLogic, Ms. Wilson served as Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc. from 1999 to 2001. Prior to 1999, Ms. Wilson worked for Deloitte & Touche LLP for ten years, serving clients in both the medical and technology fields. Ms. Wilson is a Certified Public Accountant (inactive) in the State of California and received a B.S. in Business from the University of California, Berkeley.

Heather McSharry

 Ms. Heather Ann McSharry has been appointed as Director of Jazz Pharmaceuticals PLC effective May 2, 2013. Ms. McSharry brings almost 30 years of experience in multiple international industries including healthcare, consumer goods, and financial services, most recently as Managing Director Ireland of Reckitt Benckiser, a multinational health, home and hygiene consumer products company and previously as Managing Director of Boots Health Care Ireland Limited.

Norbert Riedel

 Professor Dr. Norbert G. Riedel, Ph.D., has been appointed as Director of Jazz Pharmaceuticals PLC effective May 2, 2013. Dr. Riedel is a retired executive of the pharmaceutical industry bringing scientific, drug discovery and development, and commercial experience to the board, with over 20 years of experience in the biotechnology and pharmaceutical industry, most recently as Chief Science and Innovation Officer of Baxter International.

Peter Gray

 Mr. Peter Gray has been appointed as Non-Executive Director of Jazz Pharmaceuticals PLC, effective May 2, 2013. Mr. Gray brings over 20 years of experience in the pharmaceutical industry, most recently as Chief Executive Officer of ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and previously as Executive Vice President and Chief Financial Officer of Elan Corporation plc.

Paul Berns

 Mr. Paul L. Berns is Independent Director of Jazz Pharmaceuticals PLC. Mr. Berns is a self-employed consultant to the pharmaceutical industry. From March 2006 to August 2012, he served as the President and Chief Executive Officer, and as a member of the board of directors, of Allos Therapeutics, Inc., a pharmaceutical company acquired by Spectrum Pharmaceuticals, Inc. From July 2005 to March 2006, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Berns joined the board of directors of Anacor Pharmaceuticals, Inc. in June 2012 and has been a director of XenoPort, Inc. since 2005. Mr. Berns received a B.S. in Economics from the University of Wisconsin.

Patrick Enright

 Mr. Patrick G. Enright is Independent Director of Jazz Pharmaceuticals PLC. Since 2006, Mr. Enright has served as a Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital investment firm, where he co-led the life sciences investment practice. Mr. Enright also has life sciences operations experience, beginning his career more than 25 years ago at Sandoz (now Novartis), a pharmaceutical company. He currently serves on the boards of directors of Corcept Therapeutics Incorporated, a pharmaceutical company, and several privately held companies. In the past five years he also served as a director of Threshold Pharmaceuticals Inc. and Sequenom Inc. Mr. Enright received a B.S. from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania.

James Momtazee

 Mr. James C. Momtazee is Independent Director of Jazz Pharmaceuticals PLC. He is a member of KKR Management LLC, the general partner of KKR & Co. L.P., and he has been employed by Kohlberg Kravis Roberts & Co. L.P., or KKR, a private equity investment firm, since 1996. Funds affiliated with KKR are collectively one of shareholders. He serves on the boards of directors of HCA Inc., a healthcare services company, and Accellent Inc., a manufacturing and engineering services company. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Seamus Mulligan

 Mr. Seamus C. Mulligan is Independent Director of Jazz Pharmaceuticals PLC. Since 2006, Mr. Mulligan has served as the Executive Chairman of Circ Pharma Limited and its subsidiaries, a pharmaceutical development stage group. Mr. Mulligan served as Chief Business Officer, International Business Development from the Azur Merger until February 2013. Mr. Mulligan served as Azur Pharma’s Chairman and Chief Executive Officer and as a member of its board of directors from 2005 until the Azur Merger. From 1984 until 2004, he held various positions with Elan Corporation, a pharmaceutical company, most recently as its Executive Vice President, Business and Corporate Development. Previously at Elan Corporation, he held the roles of President of Elan Pharmaceutical Technologies, the drug delivery division of Elan, Executive Vice President, Pharmaceutical Operations, Vice President, U.S. Operations and Vice President, Product Development. He served as a member of the board of directors of the U.S. National Pharmaceutical Council until 2004. Mr. Mulligan received a B.Sc(Pharm) and M.Sc from Trinity College, Dublin, Ireland.

Kenneth O'Keefe

 Mr. Kenneth W. O'Keefe is Independent Director of Jazz Pharmaceuticals PLC. Since January 2011 he has been Managing Partner of, and from 1997 to January 2011, he was Managing Director of, Beecken Petty O’Keefe & Company, a private equity firm, which he co-founded. He serves on the boards of several privately held healthcare companies. He received a B.A. from Northwestern University and an M.B.A. from the University of Chicago.

Catherine Sohn

 Dr. Catherine Angell Sohn, Pharm.D., CLP, is Independent Director of Jazz Pharmaceuticals Plc. Dr. Sohn is the founder of Sohn Health Strategies, where since 2010 she has consulted to pharmaceutical, biotechnology, medical device, and consumer healthcare companies in the areas of business strategy, business development and strategic product development. She has served as a director of Landec Corporation, a material sciences company, since November 2012. From 1982 to 2010, she was with GlaxoSmithKline plc, a pharmaceutical company (and with SmithKline Beecham plc before its merger with GlaxoWellcome plc), where she served most recently as Senior Vice President, Worldwide Business Development and Strategic Alliances in the GSK Consumer Healthcare division, and before that, she held a series of positions in Medical Affairs, Pharmaceutical Business Development, U.S. Product Marketing, and global strategic product development in the pharmaceutical division. Dr. Sohn started her career as Assistant Professor of Clinical Pharmacy at the University of the Sciences in Philadelphia, where she currently holds the position of Dean’s Professor. She received a Pharm.D. from the University of California, San Francisco, School of Pharmacy. She also received a Certificate of Professional Development from The Wharton School at the University of Pennsylvania.

Rick Winningham

 Mr. Rick E. Winningham is Independent Director of Jazz Pharmaceuticals PLC. Since 2001, he has served as the Chief Executive Officer and since 2010, as Chairman of the board of directors of Theravance, Inc., a biopharmaceutical company. From 1986 to 2001, he held various positions with a pharmaceutical company, Bristol-Myers Squibb and its predecessor Bristol-Myers, including serving as the President of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and, from 2000 to 2001, as its President of Global Marketing. He is a member of the board of directors of the California Healthcare Institute (CHI) and is also a member of the External Advisory Board of Directors for the College of Business and Administration and Business Hall of Fame at Southern Illinois University. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.

Katherine Littrell

Insider Trading

Name Shares Traded Price

COZADD BRUCE C

 4,000 $58.52

MCSHARRY HEATHER ANN

 4,000 $0.00

RIEDEL NORBERT G

 4,000 $0.00

GRAY PETER

 4,000 $0.00

COZADD BRUCE C

 1,000 $60.00

COZADD BRUCE C

 4,000 $54.52

COZADD BRUCE C

 5,299 $45.27

COZADD BRUCE C

 182 $1.25

COZADD BRUCE C

 2,177 $11.48

COZADD BRUCE C

 7,040 $7.96

COZADD BRUCE C

 5,299 $30.18

COZADD BRUCE C

 15,902 $15.09

COZADD BRUCE C

 12,583 $19.37

COZADD BRUCE C

 4,000 $59.48

COZADD BRUCE C

 1,000 $60.00

KKR FUND HOLDINGS L P

 3,734,135 $58.28

O KEEFE KENNETH W

 400,000 $58.28

KKR FUND HOLDINGS L P

 15,865 $58.28

MULLIGAN SEAMUS

 425,000 $58.28

ENRIGHT PATRICK G

 15,720 $58.28

FALBERG KATHRYN E

 44,216 $7.35

KEEGAN FINTAN

 12,500 $0.00

COX RUSSELL J

 13,750 $0.00

ENRIGHT PATRICK G

 784,280 $58.28

WILSON KAREN J

 6,000 $0.00
» Full list on Insider Trading
Search Stocks